COBLIXRA Trademark

Trademark Overview


On Friday, March 26, 2021, a trademark application was filed for COBLIXRA with the United States Patent and Trademark Office. The USPTO has given the COBLIXRA trademark a serial number of 90606004. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Monday, July 29, 2024. This trademark is owned by Bristol-Myers Squibb Company. The COBLIXRA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pha...
coblixra

General Information


Serial Number90606004
Word MarkCOBLIXRA
Filing DateFriday, March 26, 2021
Status732 - THIRD EXTENSION - GRANTED
Status DateMonday, July 29, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 6, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely, T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, July 2, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events


Event DateEvent Description
Tuesday, March 30, 2021NEW APPLICATION ENTERED
Tuesday, October 5, 2021ASSIGNED TO EXAMINER
Friday, July 2, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, October 8, 2021PRIORITY ACTION WRITTEN
Friday, October 8, 2021PRIORITY ACTION E-MAILED
Friday, October 8, 2021NOTIFICATION OF PRIORITY ACTION E-MAILED
Wednesday, April 6, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, April 6, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, April 6, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, May 3, 2022FINAL REFUSAL WRITTEN
Tuesday, May 3, 2022FINAL REFUSAL E-MAILED
Tuesday, May 3, 2022NOTIFICATION OF FINAL REFUSAL EMAILED
Monday, October 31, 2022EXAMINERS AMENDMENT -WRITTEN
Monday, October 31, 2022EXAMINERS AMENDMENT E-MAILED
Monday, October 31, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, October 31, 2022EXAMINER'S AMENDMENT ENTERED
Monday, October 31, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 16, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 6, 2022PUBLISHED FOR OPPOSITION
Tuesday, December 6, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 31, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, July 13, 2023SOU TEAS EXTENSION RECEIVED
Thursday, July 13, 2023SOU EXTENSION 1 FILED
Thursday, July 13, 2023SOU EXTENSION 1 GRANTED
Saturday, July 15, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, January 5, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 3, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, January 3, 2024SOU EXTENSION 2 FILED
Wednesday, January 3, 2024SOU EXTENSION 2 GRANTED
Monday, July 29, 2024SOU TEAS EXTENSION RECEIVED
Monday, July 29, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 29, 2024SOU EXTENSION 3 GRANTED
Monday, July 29, 2024SOU EXTENSION 3 FILED